EP Patent

EP3973973A1 — Platform oncolytic vector for systemic delivery

Assigned to Kalivir Immunotherapeutics Inc · Expires 2022-03-30 · 4y expired

What this patent protects

This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.

USPTO Abstract

This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.

Drugs covered by this patent

Patent Metadata

Patent number
EP3973973A1
Jurisdiction
EP
Classification
—
Expires
2022-03-30
Drug substance claim
No
Drug product claim
No
Assignee
Kalivir Immunotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.